Biovie (BIVI) Enterprise Value (2013 - 2026)
Biovie (BIVI) posted Enterprise Value of -$13.1 million for Q1 2026, up 36.23% sequentially from -$20.5 million in Q4 2025, and up 43.54% YoY from -$9.1 million in Q1 2025.
Biovie (BIVI) Enterprise Value (2013 - 2026) Analysis & Trends
Biovie has reported Enterprise Value for 14 years, with the latest figure at -$13.1 million in Q1 2026.
- Quarterly Enterprise Value rose 43.54% year-over-year to -$13.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$13.1 million (up 43.54% YoY) and the FY2025 annual result came in at -$17.5 million, up 26.42% from the prior year.
- Enterprise Value climbed to -$13.1 million in Q1 2026 per BIVI's latest filing, from -$20.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$13.1 million in Q1 2026 and troughed at -$45.7 million in Q4 2022.
- A 5-year average of -$23.5 million and a median of -$21.2 million in 2022 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 313.19% in 2022, then jumped 55.79% in 2023.
- Over 5 years, Enterprise Value stood at -$45.7 million in 2022, then surged by 55.79% to -$20.2 million in 2023, then fell by 20.63% to -$24.4 million in 2024, then rose by 15.82% to -$20.5 million in 2025, then surged by 36.23% to -$13.1 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$13.1 million, -$20.5 million, and -$25.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Biovie | 13.55 Mn | 13.55 Mn | - | -9.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.00 Mn |
| Mar 31, 2026 | -13.10 Mn |
| Dec 31, 2025 | -20.54 Mn |
| Sep 30, 2025 | -25.00 Mn |
| Jun 30, 2025 | -17.54 Mn |
| Mar 31, 2025 | -23.20 Mn |
| Dec 31, 2024 | -24.40 Mn |
| Sep 30, 2024 | -20.02 Mn |
| Jun 30, 2024 | -23.84 Mn |
| Mar 31, 2024 | -30.35 Mn |
| Dec 31, 2023 | -20.23 Mn |
| Sep 30, 2023 | -21.20 Mn |
| Jun 30, 2023 | -19.46 Mn |
| Mar 31, 2023 | -31.28 Mn |
| Dec 31, 2022 | -45.75 Mn |
| Sep 30, 2022 | -21.23 Mn |
| Jun 30, 2022 | -18.64 Mn |
| Mar 31, 2022 | -24.51 Mn |
| Dec 31, 2021 | -30.39 Mn |
| Sep 30, 2021 | -20.49 Mn |